Trial
NCT04820842
A Study of TAK-994 in Adults With Narcolepsy
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Takeda
Collaborators
—
Condition
Narcolepsy Type 1 (NT 1)
Intervention
TAK-994
Why stopped
A safety signal has emerged in Phase 2 studies of TAK-994. As an immediate precautionary measure, Takeda has suspended dosing of patients and has decided to stop Phase 2 studies early.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-12-26